トランスサイレチンアミロイド心筋症（ATTR-CM）治療の世界市場レポート 2025年

トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年には複合年間成長率（CAGR）28.2%で359億3,000万米ドルに成長します。予測期間の成長は、トランスサイレチンアミロイドーシスの有病率の増加、神経障害診断の増加、高齢化人口の増加、この稀な障害の症状を治療するための特異的な薬剤に対する需要の増加、ヘルスケア需要の全体的な増加に起因すると考えられます。この期間の主な動向としては、新しい診断技術の開発、治療管理のための革新的技術、トランスサイレチンアミロイドーシスの標的治療、診断方法の発展、心臓MRI技術の向上などが挙げられます。

慢性疾患の有病率の増加が、今後のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場の成長を牽引すると予想されます。慢性疾患は、進行が緩やかで1年以上続くこともあり、しばしば継続的な医療を必要とする長期にわたる疾患です。慢性疾患の増加は、人口の高齢化、座りがちなライフスタイル、不健康な食生活、肥満率の上昇、環境汚染物質への暴露などの要因によるものです。トランスサイレチン型アミロイド心筋症の治療は、トランスサイレチンタンパク質を安定化させ、アミロイドの蓄積を抑え、心機能を改善し、症状を緩和することで、関連する慢性疾患の管理に役立ちます。例えば、2023年9月、世界保健機関（WHO）は、非伝染性疾患（NCDs）または慢性疾患が原因で年間4,100万人が死亡し、世界の死亡者数の74％を占めていると報告しました。その内訳は、心血管疾患が1,790万人、がんが930万人、慢性呼吸器疾患が410万人、糖尿病が200万人となっています。したがって、慢性疾患の有病率の増加がトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場の成長を促進しています。

トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場の企業は、トランスサイレチン（TTR）タンパク質を標的にして安定化させたり、心臓のアミロイド線維の蓄積を抑えたりする経口薬など、革新的な治療法の開発にも注力しています。経口処方薬とは、医療従事者の処方に従って、通常錠剤、カプセル剤、液剤などの形で口から服用する薬剤のことです。例えば、2024年11月、米国のバイオテクノロジー企業であるブリッジバイオ・ファーマ社は、トランスサイレチン型アミロイド心筋症（ATTR-CM）の成人に対する経口治療薬であるアトルビー（アコラミディス）の承認を米国食品医薬品局（FDA）から取得しました。この薬はTTRタンパク質を安定化させ、心臓に関連する死亡や入院を減少させる。臨床試験では、忍容性が高く、疾患の根本原因を標的とすることで迅速な効果が得られることが実証されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界トランスサイレチンアミロイド心筋症（ATTR-CM）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：成長率分析
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場の実績：規模と成長, 2019-2024
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界トランスサイレチンアミロイド心筋症（ATTR-CM）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トランスサイレチン安定剤
• 非ステロイド性抗炎症薬（NSAID）
• RNAi療法
• その他のタイプ
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 野生型ATTRアミロイドーシス
• 遺伝性ATTRアミロイドーシス
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場トランスサイレチン安定剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タファミディス
• ジフルニサル
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場非ステロイド性抗炎症薬（NSAID）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アスピリン
• イブプロフェン
• その他のNSAIDs
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場RNAi療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• パティシラン
• ヴトリシラン
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子サイレンシング療法
• 免疫療法のアプローチ
• 新興の低分子治療法

第7章 地域別・国別分析

• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：競合情勢
• トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novo Nordisk A/S
• Regeneron Pharmaceuticals Inc.
• MedStar Health Inc
• Alnylam Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc
• BridgeBio Pharma Inc.
• Prothena Corporation plc
• Intellia Therapeutics Inc.
• Alexion Pharmaceuticals Inc.
• Neurimmune Holding AG
• SOM Biotech S.L
• Corino Therapeutics Inc
• Eidos Therapeutics Inc
• CRISPR Therapeutics AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場2029：新たな機会を提供する国
• トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場2029：新たな機会を提供するセグメント
• トランスサイレチンアミロイド心筋症（ATTR-CM）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment involves medical therapies and interventions aimed at managing this progressive, life-threatening condition, which is caused by the accumulation of misfolded transthyretin (TTR) proteins in the heart. This buildup leads to restrictive cardiomyopathy and heart failure.

The main treatment types for ATTR-CM include transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other treatments. Transthyretin stabilizers work by preventing the misfolding of transthyretin proteins, thereby reducing amyloid deposits and slowing the progression of the disease. Clinical indications for treatment include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. These treatments are used by various end users, including hospitals, home care settings, specialty clinics, and others.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market statistics, including the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry global market size, regional shares, competitors with the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market share, detailed transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry. This transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.32 billion in 2025 at a compound annual growth rate (CAGR) of 28.5%. The growth during the historic period can be attributed to the rising prevalence of transthyretin amyloid cardiomyopathy, an increasing occurrence of transthyretin amyloidosis among geriatric patients, greater awareness among healthcare professionals and patients, as well as improvements in healthcare services and overall awareness.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.93 billion in 2029 at a compound annual growth rate (CAGR) of 28.2%. The projected growth in the forecast period can be attributed to the increasing prevalence of transthyretin amyloidosis, a rise in the diagnosis of neuropathic disorders, the growing aging population, a higher demand for specific drugs to treat the symptoms of this rare disorder, and an overall increase in healthcare demand. Key trends during this period include the development of new diagnostic technologies, innovative techniques for therapy management, targeted treatments for transthyretin amyloidosis, advancements in diagnostic methods, and improvements in cardiac MRI techniques.

The increasing prevalence of chronic diseases is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. Chronic diseases are long-lasting conditions that progress slowly and can last for a year or more, often requiring ongoing medical care. The rise in chronic diseases is due to factors such as aging populations, sedentary lifestyles, unhealthy diets, rising obesity rates, and exposure to environmental pollutants. Treatment for transthyretin amyloid cardiomyopathy helps stabilize the transthyretin protein, reduce amyloid buildup, improve heart function, and alleviate symptoms, which helps in managing related chronic conditions. For example, in September 2023, the World Health Organization reported that 41 million deaths annually are caused by non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of global deaths. Among these, 17.9 million were due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the growing prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are also focusing on developing innovative treatments, such as oral medications to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medications are drugs that are taken by mouth, usually in the form of tablets, capsules, or liquid solutions, as prescribed by a healthcare provider. For instance, in November 2024, BridgeBio Pharma Inc., a U.S.-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Attruby (acoramidis), an oral treatment for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This medication stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have demonstrated that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.

In January 2022, AstraZeneca Plc, a UK-based pharmaceutical company, entered into a partnership with Neurimmune AG, a Switzerland-based biopharmaceutical company. Together, they aim to develop NI006 for the treatment of ATTR-CM, targeting amyloid deposits in the heart. This collaboration seeks to address the growing need for effective treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).

Major players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG.

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transthyretin amyloid cardiomyopathy (ATTR-CM) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on transthyretin amyloid cardiomyopathy (attr-cm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for transthyretin amyloid cardiomyopathy (attr-cm) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The transthyretin amyloid cardiomyopathy (attr-cm) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
• 2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
• 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
• 2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
• 3) By RNAi Therapy: Patisiran; Vutrisiran
• 4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies
• Companies Mentioned: Pfizer Inc.; Bayer AG.; AstraZeneca Plc; GlaxoSmithKline Plc.; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Characteristics

3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends And Strategies

4. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Rate Analysis
• 5.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Total Addressable Market (TAM)

6. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation

• 6.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transthyretin Stabilizers
• Nonsteroidal Anti-inflammatory Drugs (NSAID)
• RNAi Therapy
• Other Types
• 6.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wild type ATTR Amyloidosis
• Hereditary ATTR amyloidosis
• 6.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tafamidis
• Diflunisal
• 6.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspirin
• Ibuprofen
• Other NSAIDs
• 6.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patisiran
• Vutrisiran
• 6.7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Silencing Therapies
• Immunotherapy Approaches
• Emerging Small Molecule Therapies

7. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regional And Country Analysis

• 7.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 8.1. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 9.1. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 9.2. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 10.1. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 11.1. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 11.2. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 12.1. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 13.1. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 14.1. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 14.2. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 15.1. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 15.2. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 16.1. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 17.1. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 18.1. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 19.1. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 20.1. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 21.1. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 21.2. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 22.1. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 23.1. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 23.2. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 24.1. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 24.2. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 25.1. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 25.2. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 26.1. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 26.2. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 27.1. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 28.1. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 28.2. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 29.1. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 29.2. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape
• 30.2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Other Major And Innovative Companies

• 31.1. Novo Nordisk A/S
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. MedStar Health Inc
• 31.4. Alnylam Pharmaceuticals Inc
• 31.5. Ionis Pharmaceuticals Inc.
• 31.6. Akcea Therapeutics Inc
• 31.7. BridgeBio Pharma Inc.
• 31.8. Prothena Corporation plc
• 31.9. Intellia Therapeutics Inc.
• 31.10. Alexion Pharmaceuticals Inc.
• 31.11. Neurimmune Holding AG
• 31.12. SOM Biotech S.L
• 31.13. Corino Therapeutics Inc
• 31.14. Eidos Therapeutics Inc
• 31.15. CRISPR Therapeutics AG

32. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

34. Recent Developments In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

35. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer